Table 3.

The role of oxidative stress-based strategies in immunotherapies

Drugs	Mechanism	ROS	Effects	Tumors	References
T-Fulips	Improve the antioxidant capacity of T cells	NA	Anti-tumor	Breast cancer, colon cancer, and melanoma	[224]
				Melanoma	[560]
Venetoclax	Damage the respiratory chain	Increase	Anti-tumor	Acute myeloid leukemia	[561]
IL-15	Activate the Trx system of NK cells	NA	Anti-tumor	Chronic myelogenous leukemia and non-small cell lung cancer	[563]
Zr-CeO Nanozyme	SOD-like and CAT-like enzyme activation	Decrease	Anti-tumor	Renal cancer and breast cancer	[25]
IPI-549	Inhibit PI3K/AKT pathway	Decrease	Anti-tumor	Colon cancer	[567]
β-Glucan	Train TAN to generate ROS	Increase	Anti-tumor	Lung cancer and melanoma	[564]
M-H@Lip-ZA	Kill M2-TAM utilizing ROS	Increase	Anti-tumor	Breast cancer	[569]
ICG/AuNR@BCNP	Induce ICD by tumor cell ERS	Increase	Anti-tumor	Glioblastoma and melanoma	[575]
NP-I-CA-TPP	Induce ICD by consuming GSH	Increase	Anti-tumor	Osteosarcoma	[581]
PPIR780-ZMS	Induce ICD by CDT	Increase	Anti-tumor	Melanoma	[578]
Cardiac Glycosides	Induce ICD by inhibiting sodium–potassium ATPase	Increase	Anti-tumor	Breast, colorectal, head and neck, and hepatocellular carcinoma	[579]
Micheliolide	Induce ICD by inhibiting TrxR	Increase	Anti-tumor	Hepatocellular carcinoma	[580]
PLNPCu	Induce ICD by Fenton-like reaction	Increase	Anti-tumor	Breast cancer	[577]

IL-15 interleukin-15, CAT catalase, PI3Kγ phosphoinositide 3‐kinase gamma, TAN tumor-associated neutrophil, M2-TAM M2-like tumor-associated macrophage, ICD immunogenic cell death